Journal of Medical Ethics 43 (12):857-860 (2017)

Abstract
The ability of adolescents to access safe and effective new products for HIV prevention and treatment is optimised by adolescent licensure at the same time these products are approved and marketed for adults. Many adolescent product development programmes for HIV prevention or treatment products may proceed simultaneously with adult phase III development programmes. Appropriately implemented, this strategy is not expected to delay licensure as information regarding product efficacy can often be extrapolated from adults to adolescents, and pharmacokinetic properties of drugs in adolescents are expected to be similar to those in adults. Finally, adolescents enrolled in therapeutic HIV prevention and treatment research can be considered adults, based on US Food and Drug Administration regulations and the appropriate application of state law. The FDA permits local jurisdictions to apply state and local HIV/sexually transmitted infection minor treatment laws so that adolescents who are HIV-positive or at risk of contracting HIV may be enrolled in therapeutic or prevention trials without obtaining parental permission.
Keywords No keywords specified (fix it)
Categories (categorize this paper)
DOI 10.1136/medethics-2016-103600
Options
Edit this record
Mark as duplicate
Export citation
Find it on Scholar
Request removal from index
Revision history

Download options

PhilArchive copy


Upload a copy of this paper     Check publisher's policy     Papers currently archived: 59,916
Through your library

References found in this work BETA

Add more references

Citations of this work BETA

No citations found.

Add more citations

Similar books and articles

Adolescent Hypocrisy.John Mitchell - 1975 - Journal of Moral Education 5 (1):19-23.

Analytics

Added to PP index
2017-11-24

Total views
24 ( #443,268 of 2,433,197 )

Recent downloads (6 months)
1 ( #463,180 of 2,433,197 )

How can I increase my downloads?

Downloads

My notes